Health
Johnson & Johnson SARS-CoV-2 vaccine shows promise in clinical trials – News-Medical.Net
A new study shows that a single immunization with a low dose of the Ad26.COV2.S vaccine – also known as the ‘Johnson & Johnson vaccine’ – effectively protected…
Many countries have now started to roll out vaccination efforts to contain the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes the coronavirus disease 2019 (COVID-19).
One of the candidate vaccines, the adenovirus serotype 26 (Ad26) vector-based vaccine expressing an optimized SARS-CoV-2 spike (Ad26.COV2.S) or JNJ-78436735, is now in Phase 3 of human trials.
Developed by Janssen Vaccines (Johnson & Johnson) and Beth Israel Deaconess Medical Center…
-
Noosa News18 hours agoQueensland weather forecast sees sunny weather for last week of winter
-
General21 hours agoFirst home buyers score early access to deposit scheme
-
Noosa News20 hours agoForum responds to urgent homelessness issues in Nambour
-
Business16 hours agoWhy the Betashares Nasdaq 100 ETF could be a perfect buy and hold pick